Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas

Pediatric Blood and Cancer

Volumn 59, Issue 5, 2012, Pages 854-858

  Rapkin, Louis ^a   Qayed, Muna ^a   Brill, Pam ^a   Martin, Melissa ^a   Clark, Dana ^a   George, Bradley A ^a   Olson, Thomas A ^a   Wasilewski Masker, Karen ^a   Alazraki, Adina ^a   Katzenstein, Howard M ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Docetaxel; Gemcitabine; Recurrent; Refractory; Sarcoma

Indexed keywords

BEVACIZUMAB; CREATININE; DOCETAXEL; GEMCITABINE; ZOLEDRONIC ACID;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; COHORT ANALYSIS; DESMOPLASTIC SMALL ROUND CELL TUMOR; DRUG FEVER; EWING SARCOMA; FEMALE; HUMAN; HYPERCALCEMIA; INFANT; MALE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OSTEOSARCOMA; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RHABDOMYOSARCOMA; SCHOOL CHILD; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HEMATOLOGIC DISEASES; HUMANS; INFANT; MALE; NEOPLASM GRADING; RECURRENCE; RETROSPECTIVE STUDIES; SARCOMA; SURVIVAL RATE; TAXOIDS; TIME FACTORS;

EID: 84865641965     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24101     Document Type: Article

References (13)

1. Pizzo PA, Poplack DG. Principles and practice of pediatric oncology, 6th edition. Philadelphia: Wolters Kluwer/Lippincott Williams, Wilkins Health; 2011.
2. Punyko JA, Mertens AC, Baker KS, et al. Long-term survival probabilities for childhood rhabdomyosarcoma. A population-based evaluation. Cancer 2005; 103: 1475-1483.
3. Pakos EE, Nearchou AD, Grimer RJ, et al. Prognostic factors and outcomes for osteosarcoma: An international collaboration. Eur J Cancer 2009; 45: 2367-2375.
4. Esiashvili N, Goodman M. Marcus RB Jr. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data. J Pediatr Hematol Oncol 2008; 30: 425-430.
5. Plunkett W, Huang P, Searcy CE, et al. Gemcitabine: Preclinical pharmacology and mechanisms of action. Semin Oncol 1996; 23: 3-15.
6. Reid JM, Qu W, Safgren SL, et al. Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors. J Clin Oncol 2004; 22: 2445-2451.
7. Bissery MC, Guenard D, Gueritte-Voegelein F, et al. Experimental antitumor activity of taxotere (RP56976, NSC 628503), a taxol analogue. Cancer Res 1991; 51: 4845-4852.
8. Seibel NL, Blaney SM, O'Brien M, et al. Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: A collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial. Clin Cancer Res 1999; 5: 733-737.
9. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial. J Clin Oncol 2002; 20: 2824-2831.
10. Navid F, Willert JR, McCarville MB, et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 2008; 113: 419-425.
11. Mora J, Cruz CO, Parareda A, et al. Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel. J Pediatr Hematol Oncol 2009; 31: 723-729.
12. Lee EM, Rha SY, Lee J, et al. Ahn JH Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma. Cancer Chemother Pharmacol 2011; Sep 30. [Epub ahead of print].
13. Zwerdling T, Krailo M, Monteleone P, et al. Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: A report from the Children's Oncology Group. Cancer 2006; 106: 1821-1828.